Targeting Inflammation in Acne: Current Treatments and Future Prospects

Cruz, Sebastian A.; Vecerek, Natalia; Elbuluk, Nada

doi:10.1007/s40257-023-00789-1

Cited by 13 publications

(6 citation statements)

References 131 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…When simulated by interleukin-23 (IL-23), T-helper 17 (Th17) cells enhance the production of IL-17, upregulating the inflammatory response. The IL-23/IL-17 axis is found to be active in acne lesions, with significant elevations in IL-23 and other Th17-related cytokines [13][14][15]. This pathway underlies several inflammatory skin conditions, including psoriasis, hidradenitis suppurativa (HS), atopic dermatitis (AD), alopecia areata, pityriasis rubra pilaris, pemphigus, and systemic sclerosis [16].…”

Section: Discussionmentioning

confidence: 99%

Use of Interleukin-12/23 Inhibitor for the Management of Acne Fulminans

Gier,

Israeli,

Cusick

et al. 2023

Cureus

View full text Add to dashboard Cite

Acne fulminans (AF) is a rare disorder marked by severe eruptions of inflamed nodules, hemorrhagic crusts, and ulcers accompanied by systemic symptoms and often laboratory abnormalities. Commonly affecting adolescent males with pre-existing acne, AF has been associated with isotretinoin therapy and elevated testosterone levels. With unknown pathogenesis, lesions frequently involve the trunk and face and are managed standardly with corticosteroids and isotretinoin. Uncontrolled or recurrent cases pose challenges due to prolonged high-dose corticosteroid use with increased scarring. In this study, we present a case of AF in a 17-year-old male unresponsive to corticosteroid and isotretinoin therapy, successfully treated with ustekinumab, an interleukin (IL)-12/23 inhibitor. The introduction of ustekinumab facilitated a controlled corticosteroid taper and isotretinoin dose escalation, resulting in significant clinical improvement of skin lesions and systemic symptoms. This case report underscores the potential of ustekinumab as a viable therapeutic option in the treatment of AF, particularly in cases where corticosteroid and isotretinoin combination therapy have proven ineffective.

show abstract

Section: Discussionmentioning

confidence: 99%

Use of Interleukin-12/23 Inhibitor for the Management of Acne Fulminans

Gier,

Israeli,

Cusick

et al. 2023

Cureus

View full text Add to dashboard Cite

show abstract

“…This may explain subsets of acne patients proving recalcitrant to blue light treatment ( Diogo et al., 2021 ). However, other factors including abnormalities in follicular keratinisation and sebum overproduction contribute to onset ( Cruz et al., 2023 ). Therefore, failing to address other underlying causes may also contribute to the persistence of this prevalent condition.…”

Section: Microbial Chromophoresmentioning

confidence: 99%

Illuminating microflora: shedding light on the potential of blue light to modulate the cutaneous microbiome

Serrage,

O’ Neill,

Uzunbajakava

2024

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Cutaneous diseases (such as atopic dermatitis, acne, psoriasis, alopecia and chronic wounds) rank as the fourth most prevalent human disease, affecting nearly one-third of the world’s population. Skin diseases contribute to significant non-fatal disability globally, impacting individuals, partners, and society at large. Recent evidence suggests that specific microbes colonising our skin and its appendages are often overrepresented in disease. Therefore, manipulating interactions of the microbiome in a non-invasive and safe way presents an attractive approach for management of skin and hair follicle conditions. Due to its proven anti-microbial and anti-inflammatory effects, blue light (380 – 495nm) has received considerable attention as a possible ‘magic bullet’ for management of skin dysbiosis. As humans, we have evolved under the influence of sun exposure, which comprise a significant portion of blue light. A growing body of evidence indicates that our resident skin microbiome possesses the ability to detect and respond to blue light through expression of chromophores. This can modulate physiological responses, ranging from cytotoxicity to proliferation. In this review we first present evidence of the diverse blue light-sensitive chromophores expressed by members of the skin microbiome. Subsequently, we discuss how blue light may impact the dialog between the host and its skin microbiome in prevalent skin and hair follicle conditions. Finally, we examine the constraints of this non-invasive treatment strategy and outline prospective avenues for further research. Collectively, these findings present a comprehensive body of evidence regarding the potential utility of blue light as a restorative tool for managing prevalent skin conditions. Furthermore, they underscore the critical unmet need for a whole systems approach to comprehend the ramifications of blue light on both host and microbial behaviour.

show abstract

“…Moreover, a study comparing oral isotretinoin with a 20% salicylic acid peel highlighted the efficacy of combination therapy in treating active acne [55]. Guidelines for managing acne vulgaris advocate for combination therapies and recommend standardizing the workup for patients suspected of having hormonal acne associated with polycystic ovary syndrome [56].…”

Section: Comparative Effectiveness Of Traditional Vs Emerging Treatmentsmentioning

confidence: 99%

Recent Trends in the Management of Acne Vulgaris: A Review Focusing on Clinical Studies in the Last Decade

Jaiswal,

Jawade,

Madke

et al. 2024

Cureus

View full text Add to dashboard Cite

Acne vulgaris is a prevalent chronic inflammatory skin condition with significant implications for quality of life, particularly among adolescents and young adults. Recent advancements in understanding its pathophysiology and developing novel therapeutic modalities have reshaped the landscape of acne management. This review provides an overview of recent trends in acne management, focusing on clinical studies conducted in the past decade. Key findings include insights into acne pathogenesis, emerging treatment modalities, comparative effectiveness of traditional and emerging therapies, and considerations for patient-centered care. The review underscores the importance of staying updated with recent clinical studies to provide evidence-based care and optimize patient treatment outcomes. Moreover, it highlights the need for continued research efforts to develop personalized treatment approaches, explore combination therapies, and address the psychosocial impact of acne. Collaborative endeavors between clinicians and researchers are essential to advance the field of acne management and improve patient outcomes.

show abstract

Targeting Inflammation in Acne: Current Treatments and Future Prospects

Cited by 13 publications

References 131 publications

Use of Interleukin-12/23 Inhibitor for the Management of Acne Fulminans

Use of Interleukin-12/23 Inhibitor for the Management of Acne Fulminans

Illuminating microflora: shedding light on the potential of blue light to modulate the cutaneous microbiome

Recent Trends in the Management of Acne Vulgaris: A Review Focusing on Clinical Studies in the Last Decade

Contact Info

Product

Resources

About